This clinical research study is investigating different doses of a study drug called ARX517, to see which dose is safe and has the fewest side effects, and whether or not it is effective in reducing tumor size in participants with prostate cancer or advanced solid tumor(s) with known prostate-specific membrane antigen (PSMA) expression who failed prior standard therapies.
   

The purpose of this study is to test a novel assessment of social feedback in adults with depression. It aims to study the association between activity levels, mood, and social aspects of life over the course time.

This is a research study to evaluate if the oral medication doxycycline can slow lung damage caused by emphysema in people who also have HIV. This study will also evaluate the safety and tolerability of doxycycline.

The purpose of this study is to evaluate a study drug called CFI-400945, either by itself or in combination with one of two chemotherapy drugs, known as azacitidine or decitabine. The study aims to determine how safe this drug is at different doses, with food, and in combination with azacitidine or decitabine, and to measure how well each combination works for acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML).

The purpose of this study is to look at combining the study drug IMGN632 with standard therapies (azacitidine and/or venetoclax) for acute myeloid leukemia (AML). The study will look at what effects (both good and/or bad) this combination has on the cancer, how well this combination works to treat cancer, and what a safe dose of the study drug is.

IMGN5632 is considered experimental, meaning it has not yet been approved by the U.S. Food and Drug Administration (FDA) or other health authorities.

Participants will receive IMGN5632 in combination with venetoclax andazacitidine.

The purpose of this clinical research study to find out if the experimental drug, IDE397, is safe and helpful in those who have any type of cancer that is considered a “solid tumor” (not a blood cancer) that is caused by an error in the tumor DNA associated with the gene, methylthioadenosine phosphorylase (MTAP). The loss of the MTAP gene is an error seen in many different types of cancers. Participants must have loss of the MTAP gene in order to participate in the study.
   

This is a clinical trial for adults who have been diagnosed with relapsed or refractory multiple myeloma.
   

The purpose of the study is to see if short course radiation treatment to the tumor combined with two investigational drugs AB928 and AB122 will help in eliminating the tumor and thereby increase response to the treatment in patients with rectal cancer.
   

This is a randomized study comparing 5 radiation therapy treatments to 2 radiation therapy treatments with MRI guidance in patients with prostate cancer. The study will assess the potential benefit of limiting radiation doses received by normal tissues, namely the bladder and the rectum, with advanced MRI image guidance and to compare urinary and bowel side effects between the two treatment options.  Prostate cancer cure and control and quality of life will also be examined. 

Learn more about the trial details in this informational video:

This is a trial for adults who have a diagnosis of a malignant (cancerous) brain tumor and have either been newly diagnosed with glioblastoma and completed standard chemotherapy and radiation or have a recurrence of glioblastoma (the tumor has come back).